FraAP / Sapience Therap - LARVOL DELTA

FraAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in HNSCC models (AACR 2025) - "Further, in a HNSCC subcutaneous xenograft model, administration of FraAP results in significant tumor growth inhibition, demonstrating the anti-cancer potential of targeting the AP-1 complex. In summary, these data support FraAP as a potent peptide antagonist of the AP-1 transcription factor family that warrants further development as a potential therapeutic option for AP-1 driven tumors."

Preclinical • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ANXA5 • CDH1 • CDH2 • FRA1